No 10Y consistency score yet for revenue — the window needs more comparable quarters.
Valuation vs own 10Y history: P/S N/A · No P/S — trailing revenue unavailable or non-positive.
Annualized revenue (TTM) · by quarter, last 27
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
The latest delayed quote for ORIC Pharmaceuticals, Inc. (ORIC) stock was $12.01 as of Oct 6, 2026, 12:25 PM EDT, down 3.88% from the previous close.
Longer view (total return, dividends reinvested): past 12 months -13.4% · 3-year avg +25.7%/yr · 5-year avg -8.7%/yr
ORIC Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm dedicated to discovering and advancing innovative treatments for cancer patients across the United States.
Biotechnology · South San Francisco, CA
Next Earnings Date
Nov 12, 2026
37 days away
EPS Estimate
-0.40
Revenue Est.
N/A
Last Quarter Results
EPS
$-0.38
vs Estimate
$-0.36
Revenue
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1ORIC | $1.24B | $12.01 | -3.88% | -13.37% | -8.73% | N/A | N/A |
| 2OMDA | $1.23B | $20.62 | -1.56% | -4.27% | N/A | N/A | vs ORIC |
| 3KARD | $1.27B | $14.18 | -6.95% | N/A | N/A | N/A | vs ORIC |
| 4CRON | $1.22B | $3.26 | +0.31% | +25.83% | -9.92% | +13.62% | vs ORIC |
| 5INNV | $1.22B | $8.97 | -0.36% | +79.14% | +5.55% | N/A | vs ORIC |
| 6MNKD | $1.21B | $3.79 | -0.69% | -33.55% | -4.18% | +1.97% | vs ORIC |
forward FY estimate
N/A
$0.00
vs Estimate
$0.00
Consensus Rating
Based on 14 analysts
Average Price Target
$21.43
+78.5% upside
Low
$14.00
Current
$12.01
High
$27.00
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $-0.41 | $-0.38 | $-0.36 | 9 |
| Quarter ending Dec 2026 | $-0.43 | $-0.40 | $-0.39 | 9 |
| Quarter ending Mar 2027 | $-0.41 | $-0.41 | $-0.41 | 6 |
| Quarter ending Jun 2027 | $-0.42 | $-0.42 | $-0.42 | 3 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2026 | $-1.58 | $-1.50 | $-1.42 | 11 |
| FY 2027 | $-1.81 | $-1.66 | $-1.37 | 11 |
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $0.00 | $0.00 | $0.00 | 0 |
| Quarter ending Dec 2026 | $0.00 | $0.00 | $0.00 | 0 |
| Quarter ending Mar 2027 | $0.00 | $0.00 | $0.00 | 0 |
| Quarter ending Jun 2027 | $0.00 | $0.00 | $0.00 | 0 |
Annual
| Period | Low |
|---|
Source: FMP Analyst Consensus Estimates. Forward P/E is unavailable for the current price and estimate observations.
| Avg |
|---|
| High |
|---|
| # Analysts |
|---|
| FY 2026 | $8.22M | $8.22M | $8.22M | 12 |
| FY 2027 | $2.21M | $2.21M | $2.21M | 13 |
